Previous 10 | Next 10 |
SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of p...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...
Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfa New investigator-initiated explorative, multi-centre, open-labelled Phase I/IIa trial in 12 previously treated patients with different solid tumours, called INSIGHT-005 ...
Penny Stocks To Buy On Robinhood, Webull, Fidelity & Others To Watch This Week Penny stocks are some of the most volatile asset classes in the stock market today. But thanks to the growing interest in things like crypto and options, retail traders have pushed risk aside in exchange ...
Nabriva Therapeutics (NBRV) +51% as its Nabriva antibiotic meets primary endpoint.Pieris Pharmaceuticals (PIRS) +20%.Protagenic Therapeutics (PTIX) +11%.Zscaler (ZS) +11% on Q3 results.Urban Outfitters (URBN) +11% on Q1 results.Selecta Biosciences (SELB) +10% as board dire...
Immutep (IMMP) gains 9% premarket after The Chinese Patent Office granted a new patent number ZL201480073584.3, entitled “Combined Preparations for the Treatment of Cancer”. The new patent protects Immutep’s intellectual property relating to combination therapy ...
SYDNEY, AUSTRALIA, May 26, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a ...
SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc ...
Immutep (IMMP) rises 11.7% after announcing data from its TACTI-002 and INSIGHT-004 studies. TACTI-002: Phase II trial evaluating the combination of eftilagimod alpha (efti) with Merck's Keytruda (pembrolizumab) in treatment of non-small cell lung cancer in first and second lin...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...